Al‐Foheidi, Meteb
https://orcid.org/0000-0001-8648-9836
Mayo Clinic
King Saud bin Abdulaziz University for Health Sciences
Citations 2
Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations
Elghazaly, Hesham , Azim, Hamdy A., Curigliano, Giuseppe , Tripathy, Debu , Arun, Banu , Aapro, Matti , Piccart, Martine , Elghazawy, Hagar , Saghir, Nagi S. El , Perez, Edith A. , Poortmans, Philip , Abdel-Aziz, Hany, El‐Zawahry, Heba M., Sabry, Mohamed , Viale, Giuseppe , Gado, Neven, Leung, James , El-Arab, Lobna Ezz, Cardoso, Maria João , Al‐Foheidi, Meteb , ElMaadawy, Merit, Selim, Ashraf S. M., Kandil, Alaa , Kamal, Rasha Mohammed, Guarneri, Valentina , Abulkhair, Omalkhair , Zakaria, Omar, Golshan, Mehra, Orecchia, Roberto , El-Mahdy, Manal Mohamed, Abdel‐Aziz, Ahmed M., Eldin, Nermean Bahie, Curigliano, Giuseppe , Arun, Banu , Gligorov, Joseph , Elghazawy, Hagar I , El Saghir, Nagi S , Perez, Edith A , Conte, Pierfranco , Tripathy, Debasish , Rugo, Hope S. , Cameron, David , Swain, Sandra M. , Harbeck, Nadia , Cardoso, Fátima , Gligorov, Joseph , Penault-Llorca, Frederique Madeleine , Kassem, Loay Mohamed Hassan , Al‐Sukhun, Sana , Abdelkarim, Khaled , Conte, PierFranco , Selim, Ashraf S. M. , Палтуев, Руслан Маликович , Abdel‐Aziz, Ahmed M.
Cancer | July 10, 2024 | Volume: 130 | Issue: 19 | Pages: 3251-3271
AbstractBackgroundThe management of early breast cancer (BC) has witnessed an uprise in the use of neoadjuvant therapy and a remarkable reshaping of the systemic therapy postneoadjuvant treatment in the last few years, with the evolution of many controversial clinical situations that require consensus.MethodsDuring the 14th Breast‐Gynecological and Immuno‐Oncology International Cancer Conference held in Egypt in 2022, a panel of 44 BC experts from 13 countries voted on statements concerning debatable challenges in the neo/adjuvant treatment setting. The recommendations were subsequently updated based on the most recent data emerging. A modified Delphi approach was used to develop this consensus. A consensus was achieved when ≥75% of voters selected an answer.Results and ConclusionsThe consensus recommendations addressed different escalation and de‐escalation strategies in the setting of neoadjuvant therapy for early BC. The recommendations recapitulate the available clinical evidence and expert opinion to individualize patient management and optimize therapy outcomes. Consensus was reached in 63% of the statements (52/83), and the rationale behind each statement was clarified.
Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer
Elghazaly, Hesham , Azim, Hamdy A., Aapro, Matti , Perez, Edith A. , Anderson, Benjamin O. , Conte, PierFranco , Saghir, Nagi S. El , Yip, Cheng Har , Ghosn, Marwan , Poortmans, Philip , Shehata, Mohamed , Giuliano, Armando E. , Guarneri, Valentina , Aziz, Hany Abdel, Sabry, Mohamed , Balch, Charles M. , Orecchia, Roberto , El‐Zawahry, Heba M., Al‐Sukhun, Sana , Abdelkarim, Khaled , Kandil, Alaa , Al‐Foheidi, Meteb , El‐Shinawi, Mohamed , El-Mahdy, Manal Mohamed, Abulkhair, Omalkhair , Yang, Wentao , Aref, Adel T. , Bakkach, Joaira , Eldin, Nermean Bahie, Elghazawy, Hagar , Conte, Pierfranco , El Saghir, Nagi S , Poortmans, Philip , Al-Sukhun, Sana , Kandil, Alaa , El-Shinawi, Mohamed , Abulkhair, Omalkhair , Elghazawy, Hagar I , Rugo, Hope S. , Swain, Sandra M. , Arun, Banu , Penault-Llorca, Frederique Madeleine , Leung, Jessica W. T. , Gligorov, Joseph , Gulluoglu, Bahadir Mahmut , Фролова, Мона Александровна , Палтуев, Руслан Маликович
Cancers | May 9, 2021 | Volume: 13 | Issue: 9 | Pages: 2262
Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when ≥75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.